BOCA RATON, Fla., July 25, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) announced that its Chinese partner, Lotus Pharmaceuticals, released its catalog of drugs that projects sales exceeding $50 million.
Lotus (OTCBB:LTUS), recently joined by Gold Horse International, Inc. (OTCBB:SPEH), reached public company status in 2006 as a member of the Genesis private-to-public program. Genesis maintains an active role in both companies, as an advisor to management and participant on their boards of directors.
Explaining the source of the cataloged drugs and the projected sales revenues, Dr. Liu Zhongyi, Lotus CEO and founder, commented: "Lotus markets both drugs developed through our R&D program and licensed drugs that have proved successful internationally." While not a complete catalog listing, some of these are:
Drugs developed by Lotus presently on the Chinese market:
1. Valsartan Capsules for the treatment of medium and critical
degree high blood pressure and coronary heart disease, with annual
sales estimated at $12 million.
2. Levofloxacin lactate for injection for the treatment of infectious
diseases, with annual sales estimated at $8 million.
3. Brimonidine tartrate eye drops for the treatment of glaucoma and
ocular hypertension, with annual sales estimated at $4 million.
4. Nicergoline for injection for the treatment of cerebrovascular
disease sequela and other peripheral circulatory disorders, with
annual sales estimated at $4 million.
Drugs under license to Lotus presently on the Chinese market:
1. Sodium Aescinate for injection for the treatment of cerebral oedema
caused by different diseases, trauma, swelling caused by operations
and venous return disturbance, with annual sales estimated at
$8 million.
2. Gatifioxacin for injection for the treatment of various infectious
diseases, with annual sales estimated at $6 million.
Drugs under development by Lotus not yet on the Chinese market:
1. Valsartan Dropping Pills, a patented medicine exclusively produced
by our company for the treatment of medium and critical degree
essential hypertension, with forecasted annual sales of
$20 million.
"Lotus boasts of some of the finest and most modern facilities in the pharmaceutical industry in China. In addition, our 15 retail stores offer a complete pharmacy, while some even have gymnasiums and wellness spas. We cordially invite interested parties to tour our Beijing facilities and stores," concluded Dr. Liu.
About Genesis Technology Group, Inc.
Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that earns, enhances and markets equity positions in small to mid-sized Chinese enterprises. Commitment, dedication, and expertise are the key components to the Genesis "Mission Statement." It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined "partner companies." Genesis makes a long-term commitment with management consultation, board of director's composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. For more information, visit www.Genesis-China.net.
Safe Harbor Statement and Disclaimer
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in federal or state laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company's central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.